Leeds-based Lightico hopes to play major role in halting spread of COVID-19

A Yorkshire company which is backed by a private equity firm hopes to play a significant role in the battle to halt the spread of the coronavirus pandemic

Lightico is based in Leeds

Lightico believes research will provide evidence that its patented lights – CleanLight - can kill SARS-CoV 2, the virus that causes Covid 19.

Lightico’s managing director Mark Garrett believes CleanLight could be particularly useful for firms in the hospitality sector.

Sign up to our Business newsletter

Sign up to our Business newsletter

He said: “CleanLight is proven to kill over 80% of far more robust pathogens than the coronavirus.

Lightico’s managing director Mark Garrett

“However, UK-based field trials and lab tests are underway to specifically prove that the product is effective against the coronavirus, with results due imminently.

“CleanLight uses LED lighting panels that harness the power of Titanium Dioxide (Ti02) to clean the air of microbes, toxins and odours.

Mr Garrett added: “The science bit is hugely clever and we’re thrilled to be first to the market with CleanLight, however it’s actually a really simple product to install and we’re confident it will be an integral part in the fight against Covid.

“You install the light as you would any other lighting system, then, while they are on, they are killing the viruses and bacteria in the air, including Sars-Cov-2.”

Lightico’s inventor Paul Reynard said: “About 10 years ago I had a product prototype that a Chinese firm were interested in so, on the back of this, I moved to China and started working with the firm.

“They specialised in LED light technology. During this time I started researching other ways to incorporate LED technology into existing light based products.”

Lightico, which was formed in July and based in Leeds, is backed by the private equity firm Newmore Capital.

Mr Garrett added; “This week, our Dublin-based scientists commence trials to specifically address CleanLight’s impact on virus’ and, more specifically Sars-CoV-2, the virus that causes Covid 19.

“These results are due by the end of October and we have further field trials in NHS wards in the UK as well as office buildings, supermarkets and hospitality venues in the pipeline."